ADTX Profile
Aditxt, Inc. is a biotechnology company dedicated to advancing technologies that enhance the health of the immune system through immune mapping and reprogramming. The company’s flagship product, AditxtScore, enables individuals to understand, manage, and monitor their immune profiles. This technology provides insights into how their immune system responds to various threats, whether from external pathogens or internal autoimmune conditions, allowing for more informed healthcare decisions.
In addition to immune mapping, Aditxt is pioneering Apoptotic DNA Immunotherapy, a nucleic acid-based technology that mimics the body’s natural mechanisms for inducing tolerance to its own tissues. This innovative approach has the potential to treat a range of conditions by reprogramming the immune system to reduce or eliminate unwanted immune responses. The company’s technology aims to address critical needs in the management of autoimmune diseases, allergies, and organ transplantation.
Aditxt is also developing ADi products designed to improve outcomes in organ transplantation, including skin grafting. These products aim to minimize the risk of organ rejection and enhance the success rates of transplants. The company’s research and development efforts are supported by strategic license agreements with prestigious institutions such as Loma Linda University and Leland Stanford Junior University, which provide access to cutting-edge scientific advancements and collaborative opportunities.
Incorporated in 2017 and headquartered in Richmond, Virginia, Aditxt, Inc. was formerly known as ADiTx Therapeutics, Inc. before rebranding in July 2021. The company is committed to transforming the field of immunotherapy and improving the quality of life for individuals with immune-related conditions through its innovative technologies and strategic partnerships.
|
